Courtney D. DiNardo | UT MD Anderson Top Courtney D. DiNardo, M.D., MSCE Department of Leukemia, Division of Cancer Medicine About Dr. DiNardo Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid …

Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists - PMC Skip to main content Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov website…

Michael Andreeff | UT MD Anderson Top Michael Andreeff, M.D., Ph.D. Department of Leukemia, Division of Cancer Medicine About Dr. Andreeff Dr. Andreeff received his M.D. and Ph.D. degrees at the University of Heidelberg, Germany, and additional training and faculty appointments a…

Main AML is a devastating disease with approximately 44,000 new cases diagnosed each year in the USA and EU, and with a 5-year survival rate varying considerably with age of the patients and genetic characteristics of the disease 1 . The standard of care includes intensive combin…

Abstract Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study ( NCT01546038 ) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS). Patients received gla…

Abstract Somatic mutations in cancer are a potential source of cancer specific neoantigens. Acute myeloid leukemia (AML) has common recurrent mutations shared between patients in addition to private mutations specific to individuals. We hypothesized that neoantigens derived from …

Daniel J. DeAngelo, MD, PhD - Dana-Farber Cancer Institute | Boston, MA Email Daniel J. DeAngelo, MD, PhD Medical Oncology MAKE AN APPOINTMENT Contact Information Office Phone Number 617-582-8410 Fax 617-632-6771 Appointments 617-582-7386 617-632-6028 857-215-3262 (Inpatient Tran…

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Adv. 2026 Mar 10; 10(5):1576-1586. Berman JN, Verma A, Viola S, Alonzo TA , Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, M…

Abstract Type 1 regulatory (Tr1) T cells induced by enforced expression of IL-10 (LV-10) are being developed as a novel treatment for chemotherapy-resistant myeloid leukemias. In vivo , LV-10 cells do not cause graft vs host disease while mediating graft vs leukemia (GvL) effect …

Abstract Leukemia stem cells (LSCs) are thought to play a central role in the pathogenesis of acute leukemia and likely contribute to both disease initiation and relapse. Therefore, identification of agents that target LSCs is an important consideration for the development of new…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Branko Cuglievan | UT MD Anderson Top Branko Cuglievan, MD Department of Pediatrics, Division of Pediatrics About Dr. Branko Cuglievan Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology…

Abstract Purpose: In acute myeloid leukemia (AML), recurrent DNA methyltransferase 3A ( DNMT3A ) mutations are associated with chemoresistance and poor prognosis, especially in advanced-age patients. Gene-expression studies in DNMT3A -mutated cells identified signatures implicate…

Elias Jabbour | UT MD Anderson Top Elias Jabbour, M.D. Department of Leukemia, Division of Cancer Medicine About Dr. Jabbour Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively inv…